4.7 Article

Assessing spinal muscular atrophy with quantitative ultrasound

Journal

NEUROLOGY
Volume 75, Issue 6, Pages 526-531

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181eccf8f

Keywords

-

Funding

  1. Spinal Muscular Atrophy Foundation
  2. NIH (NIAMS) [2P01 NS040828-6A11 [co-PI]]
  3. SMA Foundation
  4. Muscular Dystrophy Association
  5. New England Research Institutes/SMA Foundation
  6. Slaney Family Fund for SMA
  7. NIH [NINDS R01NS055099 [PI], NINDS K24NS060951-01A1 [PI]]
  8. ALS Association
  9. Center for Integration of Medicine and Innovative Technology

Ask authors/readers for more resources

Objective: To assess the value of quantitative ultrasound in patients with type 2 and 3 spinal muscular atrophy (SMA). Methods: Twenty-five patients with SMA (15 type 2 and 10 type 3) and 21 normal subjects were enrolled for this observational study. Strength of biceps brachii, wrist extensors, quadriceps, and tibialis anterior were measured with hand-held dynamometry. In addition, these 4 muscles were studied with a standard ultrasound system using a 5-MHz probe, and luminosity values for each muscle and the overlying subcutaneous fat were obtained by subsequent image analysis. A luminosity ratio (LR) for each muscle was calculated by dividing the muscle by the subcutaneous fat luminosity. The LR and strength scores for all 4 muscles were averaged to provide a single summary value for each patient. Results: The LRs increased with disease severity: 1.27 +/- 0.26 for normal subjects, 2.43 +/- 0.78 for type 3 SMA, and 3.85 +/- 1.3 for type 2 SMA (p < 0.001). Taking all the normal subject and patient data together, there was a good correlation between strength and LR (r = -0.711, p < 0.001). There was also a moderate relationship between LR and strength in the patients with SMA alone (r = -0.588, p = 0.008), and, as expected, a nonsignificant relationship between LR and strength in normal subjects (r = -0.011). Conclusions: Quantitative ultrasound has the potential of serving as a marker of SMA severity and may be useful in future clinical trials. Neurology (R) 2010; 75: 526-531

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available